Deterenol

Deterenol

SCHEMBL828537

CC(C)NCC(O)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 6/20 0.67
HIF1A Q16665 3/20 0.67
TSHR P16473 3/20 0.67
ADRA1A P35348 2/20 0.67
ADRB1 P08588 4/20 0.66
KDM4E B2RXH2 4/20 0.66
MAPT P10636 3/20 0.66
TDP1 Q9NUW8 3/20 0.66
ADRB3 P13945 3/20 0.66
MTOR P42345 2/20 0.66
ALDH1A1 P00352 2/20 0.66
MAPK1 P28482 2/20 0.66
HSD17B10 Q99714 2/20 0.66
MEN1 O00255 2/20 0.66
LMNA P02545 2/20 0.66
KMT2A Q03164 2/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
HPGD P15428 1/20 0.66
NFKB1 P19838 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deterenol SCHEMBL31419987 1.00 ADRB2 (0.67) ADRB2HIF1ATSHRADRA1AADRB1
Deterenol SCHEMBL120979 0.98 ADRB2 (0.67) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL12981942 0.84 ADRB2 (0.61) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL4877935 0.83 ADRB2 (0.67) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL19329750 0.83 ADRB2 (0.67) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL10484830 0.82 ADRB2 (0.59) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL10874925 0.82 ADRB2 (0.59) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL19235706 0.82 ADRB2 (0.59) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL9183624 0.82 TSHR (0.64) ADRB2HIF1ATSHRADRA1AADRB1
SCHEMBL4564683 0.82 TSHR (0.64) ADRB2HIF1ATSHRADRA1AADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377779-B2 Carbonate prodrugs and methods of using the same ACORDA THERAPEUTICS, INC. (US) 2019-08-13 US claimed
US-20190125699-A1 TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN CIPHER PHARMACEUTICALS INC. (CA) 2019-05-02 US claimed
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. 2018-03-29 US claimed
EP-2961730-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XenoPort, Inc. (US) 2016-01-06 EP claimed
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2015-06-11 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
WO-2014134005-A2 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-09-04 WO claimed
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS XENOPORT, INC. (US) 2014-08-28 US claimed
CN-101486668-B Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof XENOPORT INC 2014-07-02 CN claimed
US-20130237607-A1 TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN ASTION DEVELOPMENT A/S (DK) 2013-09-12 US claimed
EP-1719507-A1 Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin Astion Development A/S (DK) 2006-11-08 EP claimed
WO-2006108424-A2 BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN ASTION PHARMA A/S (DK) 2006-10-19 WO claimed
US-20060235048-A1 Treatment of connective tissue diseases of the skin ASTION DEVELOPMENT A/S 2006-10-19 US claimed
US-20050239725-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XENOPORT, INC. 2005-10-27 US claimed
US-6927036-B2 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof XERO PORT, INC. (US) 2005-08-09 US claimed
US-5684018-A Acyloxyisopropyl carbamates as prodrugs for amine drugs MERCK & CO., INC. (US) 1997-11-04 US claimed
WO-1996018605-A1 ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS MERCK & CO., INC. (US) 1996-06-20 WO claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 EP claimed
US-4153677-A MICROENCAPSULATED BRONCHODILATOR AGENT, ETHYL CELLULOSE FILM STERLING DRUG INC. (US) 1979-05-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237607-A1 TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN ADRB2, ADRB1, ADRA2A ADRB2 1/4885HIF1A 2127/4885TSHR 1799/4885
US-20150158809-A9 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA ADRB2 3813/4885HIF1A 2396/4885TSHR 2534/4885
US-20060235048-A1 Treatment of connective tissue diseases of the skin ADRB2, ADRB1, ADRA2A ADRB2 1/4885HIF1A 2127/4885TSHR 1799/4885
US-20140243544-A1 METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS CPS1, CA7, NAAA ADRB2 3813/4885HIF1A 2396/4885TSHR 2534/4885
US-10377779-B2 Carbonate prodrugs and methods of using the same CA6, CA7, CA4 ADRB2 4334/4885HIF1A 413/4885TSHR 3093/4885
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 ADRB2 4334/4885HIF1A 413/4885TSHR 3093/4885
US-20190125699-A1 TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN ADRB2, ADRB1, ADRA2A ADRB2 1/4885HIF1A 2127/4885TSHR 1799/4885
US-20050239725-A1 Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof AADAC, UGT1A1, ABHD5 ADRB2 3189/4885HIF1A 2092/4885TSHR 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.